PMID- 17095328
OWN - NLM
STAT- MEDLINE
DCOM- 20070104
LR  - 20061110
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 149
IP  - 5
DP  - 2006 Nov
TI  - Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine 
      in adolescents as a sixth consecutive dose of acellular pertussis-containing 
      vaccine.
PG  - 603-610
AB  - OBJECTIVE: The safety of a booster dose of a reduced-antigen-content 
      tetanus-diphtheria-acellular pertussis (Tdap) vaccine was evaluated in 
      adolescents previously vaccinated with five doses of acellular 
      pertussis-containing vaccine. STUDY DESIGN: Adolescents (n = 319) previously 
      vaccinated with either 5 doses of diphtheria-tetanus-acellular pertussis (DTaP) 
      (n = 193) or 4 doses of DTaP plus another acellular pertussis-containing vaccine 
      received one dose each of Tdap and hepatitis A vaccine in a double-blinded, 
      randomized, crossover trial. Rates of adverse events (AEs) after vaccination with 
      Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with 
      Tdap (sixth acellular pertussis-containing vaccine dose) versus rates in these 
      same individuals after vaccination with their fifth DTaP dose were assessed. 
      RESULTS: After Tdap, pain (63.6%), redness (51.7%), and swelling (41.4%) were the 
      most frequently reported AEs. Large injection site swelling (swelling > 100 mm, 
      arm circumference increase > 50 mm or diffuse swelling interfering with daily 
      activities) occurred in three adolescents and resolved without sequelae. After 
      the sixth dose of acellular pertussis-containing vaccine, adolescents reported 
      more pain and less redness and swelling compared with incidences of these AEs 
      reported when these same individuals received their fifth DTaP dose. CONCLUSIONS: 
      These results suggest that Tdap is well tolerated as a sixth consecutive dose of 
      acellular pertussis-containing vaccine.
FAU - Zepp, Fred
AU  - Zepp F
AD  - Children's Hospital, Johannes Gutenberg University, Mainz, Germany.
FAU - Knuf, Markus
AU  - Knuf M
FAU - Habermehl, Pirmin
AU  - Habermehl P
FAU - Mannhardt-Laakmann, Wilma
AU  - Mannhardt-Laakmann W
FAU - Howe, Barbara
AU  - Howe B
FAU - Friedland, Leonard R
AU  - Friedland LR
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
SB  - IM
CIN - J Pediatr. 2006 Nov;149(5):589-91. PMID: 17095321
MH  - Adolescent
MH  - Antigens, Bacterial/*administration & dosage/*adverse effects
MH  - Child
MH  - Cross-Over Studies
MH  - Diphtheria/prevention & control
MH  - Diphtheria-Tetanus-acellular Pertussis Vaccines/*administration & dosage/*adverse 
      effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Germany/epidemiology
MH  - Humans
MH  - Immunization Schedule
MH  - Incidence
MH  - Male
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Tetanus/prevention & control
MH  - Treatment Outcome
MH  - Vaccination/adverse effects
MH  - Whooping Cough/prevention & control
EDAT- 2006/11/11 09:00
MHDA- 2007/01/05 09:00
CRDT- 2006/11/11 09:00
PHST- 2005/11/21 00:00 [received]
PHST- 2006/03/15 00:00 [revised]
PHST- 2006/06/09 00:00 [accepted]
PHST- 2006/11/11 09:00 [pubmed]
PHST- 2007/01/05 09:00 [medline]
PHST- 2006/11/11 09:00 [entrez]
AID - S0022-3476(06)00553-1 [pii]
AID - 10.1016/j.jpeds.2006.06.016 [doi]
PST - ppublish
SO  - J Pediatr. 2006 Nov;149(5):603-610. doi: 10.1016/j.jpeds.2006.06.016.